Statements (101)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:cancer
gptkb:psychotherapy immunotherapy |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:alsoKnownAs |
chimeric antigen receptor T-cell therapy
|
| gptkbp:alternativeName |
CAR-T_cell_therapy
CAR_T-cell_therapy cell_therapy |
| gptkbp:approvalYear |
2017
|
| gptkbp:approved_therapies |
gptkb:Luxturna
gptkb:Strimvelis gptkb:Zynteglo gptkb:Zolgensma |
| gptkbp:approvedBy |
gptkb:FDA
1990 multiple myeloma diffuse large B-cell lymphoma B-cell acute lymphoblastic leukemia |
| gptkbp:canBe |
infectious diseases
rare diseases eye diseases neurological disorders germline somatic monogenic diseases non-viral vectors polygenic diseases viral vectors |
| gptkbp:clinicalTrialPhase |
gptkb:Phase_I
Phase II Phase III |
| gptkbp:contraindication |
active infection
uncontrolled CNS disease |
| gptkbp:cost |
hundreds of thousands of dollars
|
| gptkbp:deliveredBy |
ex vivo
in vivo |
| gptkbp:developedBy |
gptkb:Carl_June
|
| gptkbp:ethical_issues |
accessibility
cost germline modification |
| gptkbp:field |
gptkb:medicine
genetics |
| gptkbp:first_patient |
gptkb:Ashanti_DeSilva
|
| gptkbp:involves |
chimeric antigen receptor
|
| gptkbp:marketedAs |
gptkb:Gilead_Sciences
gptkb:Novartis gptkb:Bristol_Myers_Squibb |
| gptkbp:mechanismOfAction |
redirects T cells to recognize and kill cancer cells
|
| gptkbp:method |
insertion of genetic material
modification of genes replacement of faulty genes |
| gptkbp:monitors |
oncologist
hematologist |
| gptkbp:potentialComplication |
gptkb:tumor_lysis_syndrome
infections B-cell aplasia hypogammaglobulinemia |
| gptkbp:product |
gptkb:Abecma
gptkb:Tecartus gptkb:Kymriah gptkb:Yescarta gptkb:Breyanzi |
| gptkbp:purpose |
treat acquired diseases
treat genetic disorders |
| gptkbp:regulates |
gptkb:FDA
gptkb:EMA gene expression |
| gptkbp:relatedTo |
gptkb:CRISPR
genome editing gene therapy RNA therapy |
| gptkbp:requires |
leukapheresis
lymphodepleting chemotherapy personalized manufacturing |
| gptkbp:researched_since |
1970s
|
| gptkbp:researchInterest |
solid tumors
improving persistence reducing toxicity |
| gptkbp:riskFactor |
gptkb:cancer
immune response off-target effects insertional mutagenesis |
| gptkbp:sideEffect |
neurotoxicity
cytokine release syndrome |
| gptkbp:storage |
cryopreservation
|
| gptkbp:studiedBy |
gptkb:University_of_Pennsylvania
gptkb:National_Cancer_Institute |
| gptkbp:target |
cancer cells
|
| gptkbp:targetsAntigen |
gptkb:CD19
gptkb:BCMA |
| gptkbp:treatment |
gptkb:cancer
gptkb:anemia hemophilia sickle cell disease immunodeficiency cystic fibrosis muscular dystrophy |
| gptkbp:uses |
genetically engineered T cells
|
| gptkbp:bfsParent |
gptkb:Daniel_G._Anderson
gptkb:biotechnology |
| gptkbp:bfsLayer |
4
|